The University of SheffieldBrowse
The cost-effectiveness of expanding the NHS newborn 2014.pdf (420.33 kB)
Download file

The cost-effectiveness of expanding the NHS newborn bloodspot screening programme to include homocystinuria (HCU), maple syrup urine disease (MSUD), glutaric aciduria type 1 (GA1), isovaleric acidaemia (IVA), and long-chain hydroxyl acyl-CoA dehydrogenase deficiency (LCHADD) (2014)

Download (420.33 kB)
poster
posted on 2020-03-01, 12:08 authored by Alice BesseyAlice Bessey, Jim Chilcott, Suzy Paisley, Abdullah PandorAbdullah Pandor
The NHS newborn bloodspot screening programme screens all babies in England for five rare conditions. This study assessed the economics of expanding the screening programme to include five new inborn errors of the metabolism; HCU, MSUD, GA1, IVA, and LCHADD.

History

Ethics

There is no personal data or any that requires ethical approval

Policy

The data complies with the institution and funders' policies on access and sharing

Sharing and access restrictions

The data can be shared openly

Data description

  • The file formats are open or commonly used

Methodology, headings and units

  • Headings and units are explained in the files

Usage metrics

The University of SheffieldThe University of Sheffield

Categories

Keywords

NHSnewborn bloodspot screening programmeMaple syrup urine diseaseglutaric aciduria type 1 (GA1)isovaleric acidaemia (IVA)long chain hydroxyl acyl-CoA dehydrogenase deficiency (LCHADD)Health Economics

Licence

CC BY 4.0

Exports